BD Reports Third Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
BD (NYSE: BDX) reported fiscal Q3 2026 revenue of $4.983 billion, up 5.4% as reported and 4.4% FX-neutral. GAAP diluted EPS from continuing operations was $1.64 (up 4.5%), and adjusted diluted EPS was $3.23 (up 4.9%).
Year-to-date, cash from continuing operations reached $2.1 billion (+33.3%) and free cash flow $1.7 billion (+44.6%). All four segments grew mid-single digits, led by BioPharma Systems and Interventional. Following the February 2026 spin-off of its Biosciences and Diagnostic Solutions business to combine with Waters, BD now reports four segments on a continuing-operations basis.
BD updated full-year 2026 guidance, maintaining low single-digit plus GAAP revenue growth and low single-digit FX-neutral revenue growth, while raising the midpoint of adjusted diluted EPS guidance to $12.62–$12.72 from $12.52–$12.72, reflecting ongoing momentum in its “New BD” MedTech-focused portfolio.
Positive
- Q3 2026 revenue $4.983B, up 5.4% reported and 4.4% FX-neutral versus Q3 2025
- Adjusted diluted EPS $3.23, up 4.9% reported and 3.9% FX-neutral year over year
- Year-to-date cash from continuing operations $2.1B, up 33.3% versus prior year period
- Year-to-date free cash flow $1.7B, up 44.6% versus prior year period
- All four segments grew Q3 revenues 4.5%–6.6% reported; FX-neutral growth 3.2%–5.5%
- Adjusted EPS guidance raised to $12.62–$12.72 from $12.52–$12.72 for fiscal 2026
Negative
- Q3 international revenue FX-neutral growth 0.6%, below United States growth of 6.9%
- Full-year 2026 revenue growth outlook remains low single-digit on both GAAP and FX-neutral bases
News Explained
Alongside its fiscal third-quarter report, BD says
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q2 FY26 earnings | Positive | +5.9% | Revenue growth, adjusted EPS increase, buyback execution, debt retirement, and raised guidance |
| Feb 09 | Q1 FY26 earnings | Neutral | -1.3% | Mixed EPS performance, continuing-operations transition, and reaffirmed full-year guidance |
| Nov 06 | FY25 earnings | Positive | +0.6% | Quarterly and annual revenue growth, margin expansion, shareholder returns, and FY26 guidance |
| Aug 07 | Q3 FY25 earnings | Positive | +8.9% | Revenue and adjusted EPS growth, raised guidance, margin improvement, and buyback progress |
| May 01 | Q2 FY25 earnings | Neutral | -18.1% | Revenue and adjusted EPS growth, revised guidance, manufacturing investment, and segment changes |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five tag-matched earnings events produced mixed reactions, with three positive and two negative observations and a -0.82% average.
Key Terms
non-gaap financial measures financial
free cash flow financial
foreign currency-neutral basis financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Revenue of
$5.0 billion 5.4% as reported,4.4% FXN - GAAP and adjusted diluted EPS from continuing operations of
$1.64 $3.23 - Year-to-date cash from continuing operations increased
33.3% to$2.1 billion 44.6% to$1.7 billion - Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance
"We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value."
Recent Business Highlights
- Medical Essentials:
- Awarded a Vizient Innovative Technology contract for the BD® CentroVena One™ Insertion System, validating CentroVena One™ Insertion System as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety.
- BioPharma Systems:
- Announced a collaboration with EMS, one of
Brazil's leading pharmaceutical companies, to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes.
- Announced a collaboration with EMS, one of
- Interventional:
- Launched the Elyra™ Thulium Fiber Laser System, expanding BD's kidney stone care portfolio with a system designed to help urology teams enhance efficiency, versatility and procedural workflow.
- BD named to TIME's 2026 List of America's Best Companies.
- BD issued its Fiscal Year 2025 Together We Advance Corporate Sustainability Report.
Basis of Presentation— Continuing Operations
On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.
Third Quarter Fiscal 2026 Operating Results
(Millions of dollars, except per share amounts) | Three Months Ended June 30, | Reported | Foreign Currency | |
2026 | 2025 | |||
Revenues | $ 4,983 | $ 4,726 | 5.4 % | 4.4 % |
Reported Diluted Earnings per Share | $ 1.64 | $ 1.57 | 4.5 % | 3.8 % |
Adjusted Diluted Earnings per Share1 | $ 3.23 | $ 3.08 | 4.9 % | 3.9 % |
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. |
Geographic Results
Revenues (Millions of dollars) | Three Months Ended June 30, | Reported | Foreign Currency | |||||
2026 | 2025 | |||||||
$ 3,081 | $ 2,882 | 6.9 % | 6.9 % | |||||
International | $ 1,902 | $ 1,844 | 3.2 % | 0.6 % | ||||
Total Revenues | $ 4,983 | $ 4,726 | 5.4 % | 4.4 % | ||||
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. |
Segment Results
Revenues (Millions of dollars) | Three Months Ended June 30, | Reported | Foreign Currency | |||||
2026 | 2025 | |||||||
Medical Essentials2 | $ 1,675 | $ 1,602 | 4.5 % | 3.2 % | ||||
Connected Care2 | $ 1,224 | $ 1,166 | 4.9 % | 4.4 % | ||||
BioPharma Systems2 | $ 670 | $ 629 | 6.6 % | 5.2 % | ||||
Interventional2 | $ 1,414 | $ 1,328 | 6.4 % | 5.5 % | ||||
Total Revenues | $ 4,983 | $ 4,726 | 5.4 % | 4.4 % | ||||
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. |
2Effective October 1, 2025, the company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis. |
Full Year Fiscal 2026 Guidance
The company updates its full year fiscal 2026 guidance as follows; expects revenue growth toward the high end of its range and raises the midpoint of adjusted diluted EPS guidance.
Updated New BD Guidance as of August 6, 2026 | Prior New BD Guidance as of May 7, 2026 | |
GAAP Revenue Growth | Low single-digit plus | Low single-digit plus |
Revenue Growth (FXN) | Low single-digit | Low single-digit |
Adjusted Diluted EPS |
BD's guidance for full year fiscal 2026 reflects numerous assumptions that could affect its business, based on the information management has reviewed as of this date. Management will discuss its guidance and several of its assumptions on its third fiscal quarter earnings call.
The company's expected adjusted diluted EPS for fiscal 2026 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our revenue growth for our 2026 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying revenue performance for our 2026 fiscal year in relation to our underlying 2025 fiscal year performance.
Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts and news media to discuss its third quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors, at 8 a.m. (ET) Thursday, August 6, 2026. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-688-9445 (domestic) and 402-220-1371 (international) through the close of business on Thursday, August 13, 2026. A confirmation number is not needed to access the replay.
Non-GAAP Financial Measures/Financial Tables
This press release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral basis, adjusted diluted earnings per share and free cash flow. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
We present adjusted diluted earnings per share for the third quarter and the first nine months of fiscal year 2026, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, separation-related costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, certain pension settlement costs, and the impact of the extinguishment of debt.
We also present revenue growth rates for the third quarter and the first nine months of fiscal year 2026 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior period. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods.
We also present free cash flow for the first nine months of fiscal year 2026 over the corresponding prior period, which is net cash provided by continuing operating activities less capital expenditures, to provide a view of the Company's ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary expenditures given that we have certain non-discretionary obligations such as debt service that are not deducted from the measure. We believe the presentation of results of free cash flow in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior period.
New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.
Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
***
This press release and accompanying audio webcast on August 6, 2026 contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, statements relating to future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including volatility resulting from the imposition of (and changing policies around) tariffs enacted by the U.S. government (and related countermeasures by non-U.S. governments), or our ability to mitigate the impact of such tariffs, including developments regarding refunds of certain tariffs and/or the collection of remaining refunds of certain tariffs; import or export licensing requirements and other governmental restrictions; reductions in U.S. government funding for healthcare, disruptions in global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products; inflationary pressures, currency and interest rate fluctuations, global oil prices and increased borrowing costs; conditions in international markets, including geopolitical developments such as the continuation and/or escalation of evolving situations in Iran and the Middle East region (which could result in continued disruption of transportation lanes and global energy supplies, as well as increases in global oil prices and adversely affect our supply chain costs, ability to source raw materials and components and our ability to deliver product to customers), Ukraine and Asia; competitive factors, including changing customer and patient preferences and requirements, such as decreased demand for our products as a result of changes to U.S. federal and state policies (such as for pharmaceutical products and vaccines), and increased demand for products utilizing evolving technologies (including emerging technologies utilizing artificial intelligence ("AI")), as well as new products or novel medical therapies introduced by competitors; changes in research and development efforts, investment or suspension by pharmaceuticals companies with regard to vaccine development; changes in reimbursement practices and coverage policies and third-party payer cost containment measures and health insurance coverage levels and costs; decreases or delays in purchases of our products due to reduced research and development spending; product efficacy or safety concerns and related regulatory actions, changes to the labeled indications or permitted uses of our products, non-compliance with applicable regulatory requirements regarding our products, including marketing authorization, registration, quality system and manufacturing requirements (including as a result of product modifications), or other factors that could result in product recalls, field actions, lost revenue, restrictions on our ability to continue selling existing products or commercialize new products (including limitations on future product clearances or approvals and the imposition of civil penalties); increased exposure to product liability or other claims and damage to our reputation (including products we acquire through acquisitions); changes to legislation or regulations that may impact U.S. or foreign healthcare systems, changes in medical or clinical practices or in customer and patient preferences, efforts to improve compliance of healthcare practitioners, potential cuts or freezes in healthcare spending and/or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; policy and regulatory changes that may be implemented by the U.S. government, including the further elimination, downsizing and/or reduced funding of certain government agencies and programs, as well as further changes in the policy positions of such agencies (including those related to pharmaceutical products and vaccines); other new or changing laws and regulations impacting our business, including changes in tax laws, new and changing environmental laws and regulations (such as those related to sustainability, climate change or materials of concern) and new and changing cybersecurity, AI or privacy laws; other changes in laws impacting international trade or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; any adverse impact related to the development, deployment and use of AI in our products and business operations; labor disruptions; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in raw material, component, labor, duties, freight, energy and other production costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of natural disasters and public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to achieve or maintain growth of our portfolio; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission (the "SEC")); the issuance of new or revised accounting standards; our ability to execute our New BD strategy, Excellence Unleashed, as expected; and other factors discussed in BD's filings with the SEC. Tariff commentary is based on tariff policies in effect as of August 5, 2026. International trade policies, trade restrictions and tariffs (and related countermeasures and developments regarding refunds of certain tariffs) are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
Contacts:
Investors: Shawn Bevec, SVP, Investor Relations - investor.relations@bd.com
Media: Matt Marcus, VP, Public Relations - matt.marcus@bd.com
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in millions, except share and per share data)
| ||||||||||||||||||||
Three Months Ended June 30, | ||||||||||||||||||||
2026 | 2025 | % Change | ||||||||||||||||||
Revenues | $ | 4,983 | $ | 4,726 | 5.4 | |||||||||||||||
Cost of products sold | 2,668 | 2,491 | 7.1 | |||||||||||||||||
Selling and administrative expense | 1,261 | 1,163 | 8.4 | |||||||||||||||||
Research and development expense | 258 | 230 | 12.0 | |||||||||||||||||
Integration, restructuring and transaction expense | 89 | 96 | (6.9) | |||||||||||||||||
Other operating expense, net | 44 | 7 | 544.7 | |||||||||||||||||
Total Operating Costs and Expenses | 4,320 | 3,986 | 8.4 | |||||||||||||||||
Operating Income | 663 | 739 | (10.3) | |||||||||||||||||
Interest expense | (132) | (152) | (13.4) | |||||||||||||||||
Interest income | 4 | 4 | (15.8) | |||||||||||||||||
Other income (expense), net | 19 | (22) | 183.9 | |||||||||||||||||
Income from Continuing Operations Before Income Taxes | 554 | 569 | (2.7) | |||||||||||||||||
Income tax provision | 102 | 118 | (13.2) | |||||||||||||||||
Net Income from Continuing Operations | 451 | 451 | 0.1 | |||||||||||||||||
(Loss) Income from Discontinued Operations, Net of Tax | (74) | 123 | (159.8) | |||||||||||||||||
Net Income | $ | 377 | $ | 574 | (34.3) | |||||||||||||||
Basic Earnings Per Share | ||||||||||||||||||||
Income from Continuing Operations | $ | 1.64 | $ | 1.57 | 4.5 | |||||||||||||||
(Loss) Income from Discontinued Operations | (0.27) | 0.43 | (162.8) | |||||||||||||||||
Basic Earnings per Share | $ | 1.37 | $ | 2.00 | (31.5) | |||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||
Income from Continuing Operations | $ | 1.64 | $ | 1.57 | 4.5 | |||||||||||||||
(Loss) Income from Discontinued Operations | (0.27) | 0.43 | (162.8) | |||||||||||||||||
Diluted Earnings per Share | $ | 1.37 | $ | 2.00 | (31.5) | |||||||||||||||
Average Shares Outstanding (in thousands) | ||||||||||||||||||||
Basic | 274,788 | 287,170 | ||||||||||||||||||
Diluted | 275,158 | 287,223 | ||||||||||||||||||
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in millions, except share and per share data)
| ||||||||||||||||||||
Nine Months Ended June 30, | ||||||||||||||||||||
2026 | 2025 | % Change | ||||||||||||||||||
Revenues | $ | 14,183 | $ | 13,539 | 4.8 | |||||||||||||||
Cost of products sold | 7,662 | 7,646 | 0.2 | |||||||||||||||||
Selling and administrative expense | 3,703 | 3,435 | 7.8 | |||||||||||||||||
Research and development expense | 742 | 706 | 5.1 | |||||||||||||||||
Integration, restructuring and transaction expense | 729 | 277 | 162.9 | |||||||||||||||||
Other operating expense, net | 122 | 70 | 74.9 | |||||||||||||||||
Total Operating Costs and Expenses | 12,958 | 12,134 | 6.8 | |||||||||||||||||
Operating Income | 1,225 | 1,405 | (12.8) | |||||||||||||||||
Interest expense | (434) | (458) | (5.1) | |||||||||||||||||
Interest income | 16 | 31 | (47.4) | |||||||||||||||||
Other income (expense), net | 97 | (72) | 234.4 | |||||||||||||||||
Income from Continuing Operations Before Income Taxes | 904 | 906 | (0.2) | |||||||||||||||||
Income tax provision | 179 | 151 | 18.5 | |||||||||||||||||
Net Income from Continuing Operations | 725 | 755 | (4.0) | |||||||||||||||||
(Loss) Income from Discontinued Operations, Net of Tax | (276) | 430 | (164.3) | |||||||||||||||||
Net Income | $ | 449 | $ | 1,185 | (62.1) | |||||||||||||||
Basic Earnings Per Share | ||||||||||||||||||||
Income from Continuing Operations | $ | 2.59 | $ | 2.62 | (1.1) | |||||||||||||||
(Loss) Income from Discontinued Operations | (0.99) | 1.49 | (166.4) | |||||||||||||||||
Basic Earnings per Share | $ | 1.60 | $ | 4.11 | (61.1) | |||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||
Income from Continuing Operations | $ | 2.58 | $ | 2.62 | (1.5) | |||||||||||||||
(Loss) Income from Discontinued Operations | (0.98) | 1.49 | (165.8) | |||||||||||||||||
Diluted Earnings per Share | $ | 1.59 | $ | 4.10 | (61.2) | |||||||||||||||
Average Shares Outstanding (in thousands) | ||||||||||||||||||||
Basic | 280,332 | 287,997 | ||||||||||||||||||
Diluted | 281,603 | 288,693 | ||||||||||||||||||
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited; Amounts in millions)
| ||||||||||||||
June 30, 2026 | September 30, 2025 | |||||||||||||
Assets | ||||||||||||||
Cash and equivalents | $ | 708 | $ | 567 | ||||||||||
Restricted cash | 155 | 210 | ||||||||||||
Short-term investments | 1 | 8 | ||||||||||||
Trade receivables, net | 2,364 | 2,396 | ||||||||||||
Inventories | 3,316 | 3,149 | ||||||||||||
Prepaid expenses and other | 1,595 | 1,379 | ||||||||||||
Current assets of discontinued operations | — | 1,545 | ||||||||||||
Total Current Assets | 8,139 | 9,255 | ||||||||||||
Property, plant and equipment, net | 6,083 | 6,383 | ||||||||||||
Goodwill and other intangibles, net | 33,964 | 35,190 | ||||||||||||
Other assets | 2,546 | 2,383 | ||||||||||||
Noncurrent assets of discontinued operations | — | 2,114 | ||||||||||||
Total Assets | $ | 50,731 | $ | 55,325 | ||||||||||
Liabilities and Shareholders' Equity | ||||||||||||||
Current debt obligations | $ | 3,297 | $ | 1,559 | ||||||||||
Other current liabilities | 6,107 | 6,106 | ||||||||||||
Current liabilities of discontinued operations | — | 648 | ||||||||||||
Long-term debt | 13,511 | 17,620 | ||||||||||||
Long-term employee benefit obligations | 1,005 | 1,027 | ||||||||||||
Deferred income taxes and other liabilities | 2,394 | 2,632 | ||||||||||||
Noncurrent liabilities of discontinued operations | — | 342 | ||||||||||||
Shareholders' equity | 24,416 | 25,390 | ||||||||||||
Total Liabilities and Shareholders' Equity | $ | 50,731 | $ | 55,325 | ||||||||||
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited; Amounts in millions)
| ||||||||||||||
Nine Months Ended June 30, | ||||||||||||||
2026 | 2025 | |||||||||||||
Operating Activities | ||||||||||||||
Net income | $ | 449 | $ | 1,185 | ||||||||||
Less: (Loss) income from discontinued operations, net of tax | (276) | 430 | ||||||||||||
Income from continuing operations, net of tax | 725 | 755 | ||||||||||||
Depreciation and amortization | 1,697 | 1,706 | ||||||||||||
Change in operating assets and liabilities and other, net | (319) | (883) | ||||||||||||
Net Cash Provided by Continuing Operating Activities | 2,104 | 1,578 | ||||||||||||
Investing Activities | ||||||||||||||
Capital expenditures | (376) | (383) | ||||||||||||
Maturities and sales of investments | 27 | 408 | ||||||||||||
Acquisitions, net of cash acquired and adjustments | (22) | 13 | ||||||||||||
Other, net | (192) | (267) | ||||||||||||
Net Cash Used for Continuing Investing Activities | (563) | (229) | ||||||||||||
Financing Activities | ||||||||||||||
Change in short-term debt | 37 | 133 | ||||||||||||
Proceeds from long-term debt | 704 | — | ||||||||||||
Distribution from spin-off entity, net | 3,857 | — | ||||||||||||
Payments of debt | (2,696) | (1,208) | ||||||||||||
Repurchases of common stock | (2,250) | (750) | ||||||||||||
Dividends paid | (875) | (899) | ||||||||||||
Other, net | (70) | (83) | ||||||||||||
Net Cash Used for Continuing Financing Activities | (1,293) | (2,807) | ||||||||||||
Discontinued Operations | ||||||||||||||
Net cash (used for) provided by operating activities | (198) | 498 | ||||||||||||
Net cash used for investing activities | (40) | (96) | ||||||||||||
Net cash provided by (used for) financing activities | 71 | (8) | ||||||||||||
Net Cash (Used for) Provided by Discontinued Operations | (167) | 395 | ||||||||||||
Effect of exchange rate changes on cash and equivalents and restricted cash | 5 | (2) | ||||||||||||
Net increase (decrease) in cash and equivalents and restricted cash | 86 | (1,065) | ||||||||||||
Opening Cash and Equivalents and Restricted Cash | 777 | 1,792 | ||||||||||||
Closing Cash and Equivalents and Restricted Cash | $ | 863 | $ | 727 | ||||||||||
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Three Months Ended June 30, (Unaudited; Amounts in millions)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
% Change | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2026 | 2025 | % Change | 2026 | 2025 | FX Impact | Reported | FXN | 2026 | 2025 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Essentials(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 720 | $ | 680 | 5.9 | $ | 444 | $ | 452 | $ | 13 | (1.8) | (4.7) | $ | 1,164 | $ | 1,132 | $ | 13 | 2.8 | 1.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Specimen Management | 274 | 240 | 14.0 | 237 | 230 | 8 | 3.1 | (0.2) | 511 | 470 | 8 | 8.7 | 7.0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 994 | $ | 920 | 8.0 | $ | 681 | $ | 682 | $ | 21 | (0.1) | (3.2) | $ | 1,675 | $ | 1,602 | $ | 21 | 4.5 | 3.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Connected Care(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medication Management Solutions | $ | 737 | $ | 709 | 3.9 | $ | 178 | $ | 179 | $ | 6 | (0.4) | (4.0) | $ | 915 | $ | 888 | $ | 6 | 3.0 | 2.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Advanced Patient Monitoring | 189 | 176 | 7.4 | 120 | 102 | (1) | 17.1 | 17.8 | 309 | 278 | (1) | 10.9 | 11.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 926 | $ | 885 | 4.6 | $ | 297 | $ | 281 | $ | 6 | 5.9 | 3.9 | $ | 1,224 | $ | 1,166 | $ | 6 | 4.9 | 4.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioPharma Systems(1)(2) | $ | 204 | $ | 178 | 14.2 | $ | 467 | $ | 451 | $ | 9 | 3.6 | 1.6 | $ | 670 | $ | 629 | $ | 9 | 6.6 | 5.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interventional(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peripheral Intervention | $ | 294 | $ | 271 | 8.4 | $ | 258 | $ | 241 | $ | 9 | 7.2 | 3.5 | $ | 552 | $ | 512 | $ | 9 | 7.8 | 6.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Urology and Critical Care | 357 | 334 | 7.1 | 82 | 88 | — | (6.7) | (6.9) | 440 | 422 | — | 4.2 | 4.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery | 306 | 294 | 4.3 | 116 | 101 | 3 | 15.0 | 11.7 | 422 | 395 | 3 | 7.0 | 6.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 957 | $ | 898 | 6.6 | $ | 457 | $ | 430 | $ | 12 | 6.2 | 3.3 | $ | 1,414 | $ | 1,328 | $ | 12 | 6.4 | 5.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Revenues from Continuing Operations | $ | 3,081 | $ | 2,882 | 6.9 | $ | 1,902 | $ | 1,844 | $ | 48 | 3.2 | 0.6 | $ | 4,983 | $ | 4,726 | $ | 48 | 5.4 | 4.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) | Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis. |
(2) | The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Nine Months Ended June 30, (Unaudited; Amounts in millions)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
% Change | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2026 | 2025 | % Change | 2026 | 2025 | FX Impact | Reported | FXN | 2026 | 2025 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Essentials(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 2,124 | $ | 2,060 | 3.1 | $ | 1,331 | $ | 1,313 | $ | 56 | 1.4 | (2.9) | $ | 3,455 | $ | 3,373 | $ | 56 | 2.4 | 0.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Specimen Management | 772 | 721 | 7.2 | 690 | 667 | 32 | 3.5 | (1.2) | 1,463 | 1,387 | 32 | 5.4 | 3.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 2,897 | $ | 2,781 | 4.2 | $ | 2,021 | $ | 1,979 | $ | 88 | 2.1 | (2.3) | $ | 4,918 | $ | 4,760 | $ | 88 | 3.3 | 1.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Connected Care(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medication Management Solutions | $ | 2,076 | $ | 2,030 | 2.3 | $ | 502 | $ | 470 | $ | 27 | 6.8 | 1.2 | $ | 2,578 | $ | 2,500 | $ | 27 | 3.1 | 2.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Advanced Patient Monitoring | 547 | 490 | 11.7 | 350 | 317 | 5 | 10.6 | 9.1 | 897 | 806 | 5 | 11.3 | 10.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 2,623 | $ | 2,520 | 4.1 | $ | 852 | $ | 787 | $ | 31 | 8.3 | 4.4 | $ | 3,475 | $ | 3,307 | $ | 31 | 5.1 | 4.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioPharma Systems(1)(2) | $ | 532 | $ | 431 | 23.4 | $ | 1,157 | $ | 1,191 | $ | 41 | (2.8) | (6.2) | $ | 1,689 | $ | 1,622 | $ | 41 | 4.1 | 1.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interventional(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peripheral Intervention | $ | 839 | $ | 793 | 5.8 | $ | 713 | $ | 673 | $ | 29 | 6.0 | 1.6 | $ | 1,552 | $ | 1,466 | $ | 29 | 5.9 | 3.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Urology and Critical Care | 1,047 | 962 | 8.8 | 250 | 249 | 5 | 0.4 | (1.8) | 1,297 | 1,211 | 5 | 7.1 | 6.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery | 919 | 885 | 3.8 | 333 | 288 | 13 | 15.8 | 11.1 | 1,252 | 1,173 | 13 | 6.8 | 5.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 2,805 | $ | 2,640 | 6.2 | $ | 1,296 | $ | 1,209 | $ | 48 | 7.2 | 3.2 | $ | 4,101 | $ | 3,849 | $ | 48 | 6.5 | 5.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Revenues from Continuing Operations | $ | 8,857 | $ | 8,372 | 5.8 | $ | 5,326 | $ | 5,166 | $ | 208 | 3.1 | (0.9) | $ | 14,183 | $ | 13,539 | $ | 208 | 4.8 | 3.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) | Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the Company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis. |
(2) | The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS Three Months Ended June 30, (Unaudited) | |||||||||||||||||||||||||||||||||||||||||
Three Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||
2026 | 2025 | Change | Translational FX | FXN | Change % | FXN | |||||||||||||||||||||||||||||||||||
Reported Diluted Earnings per Share from Continuing Operations | $ | 1.64 | $ | 1.57 | $ | 0.07 | $ | 0.01 | $ | 0.06 | 4.5 | % | 3.8 | % | |||||||||||||||||||||||||||
Purchase accounting adjustments ( | 1.32 | 1.31 | — | ||||||||||||||||||||||||||||||||||||||
Integration costs ( | 0.15 | 0.13 | — | ||||||||||||||||||||||||||||||||||||||
Restructuring costs ( | 0.18 | 0.20 | 0.03 | ||||||||||||||||||||||||||||||||||||||
Transaction costs ( | — | 0.01 | — | ||||||||||||||||||||||||||||||||||||||
Separation-related items ( | 0.12 | — | — | ||||||||||||||||||||||||||||||||||||||
Product, litigation, and other items ( | 0.19 | 0.15 | — | ||||||||||||||||||||||||||||||||||||||
Tax impact of specified items and other tax related ( | (0.37) | (0.29) | — | ||||||||||||||||||||||||||||||||||||||
Adjusted Diluted Earnings per Share from Continuing Operations | $ | 3.23 | $ | 3.08 | $ | 0.15 | $ | 0.03 | $ | 0.12 | 4.9 | % | 3.9 | % | |||||||||||||||||||||||||||
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. |
(3) | Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition. |
(4) | Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters. |
(5) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the three months ended June 30, 2026 reflects charges to adjust the estimate of certain future product remediation costs, various legal matters, and pension settlement costs. The amount for the three months ended June 30, 2025 reflects a charge of |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS Nine Months Ended June 30, (Unaudited) | |||||||||||||||||||||||||||||||||||||||||
Nine Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||||
2026 | 2025 | Change | Translational FX | FXN | Change % | FXN | |||||||||||||||||||||||||||||||||||
Reported Diluted Earnings per Share from Continuing Operations | $ | 2.58 | $ | 2.62 | $ | (0.04) | $ | 0.05 | $ | (0.09) | (1.5) | % | (3.4) | % | |||||||||||||||||||||||||||
Purchase accounting adjustments ( | 3.95 | 5.13 | 0.01 | ||||||||||||||||||||||||||||||||||||||
Integration costs ( | 0.44 | 0.30 | — | ||||||||||||||||||||||||||||||||||||||
Restructuring costs ( | 2.15 | 0.64 | 0.05 | ||||||||||||||||||||||||||||||||||||||
Transaction costs ( | — | 0.02 | — | ||||||||||||||||||||||||||||||||||||||
Separation-related items ( | 0.26 | — | — | ||||||||||||||||||||||||||||||||||||||
Product, litigation, and other items ( | 0.68 | 0.88 | — | ||||||||||||||||||||||||||||||||||||||
Impacts of debt extinguishment ( | (0.43) | — | — | ||||||||||||||||||||||||||||||||||||||
Tax impact of specified items and other tax related ( | (1.04) | (0.95) | — | ||||||||||||||||||||||||||||||||||||||
Adjusted Diluted Earnings per Share from Continuing Operations | $ | 8.59 | $ | 8.65 | $ | (0.06) | $ | 0.11 | $ | (0.17) | (0.7) | % | (2.0) | % | |||||||||||||||||||||||||||
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. Restructuring costs for the nine months ended June 30, 2026 reflect non-cash asset impairment charges of |
(3) | Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition. |
(4) | Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters. |
(5) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the nine months ended June 30, 2026 reflects charges of |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW Nine Months Ended June 30, (Unaudited)
| ||||||||||||||||||||||||||
A | B | C=A-B | D=C/B | |||||||||||||||||||||||
2026 | 2025 | Change | % Change | |||||||||||||||||||||||
Net Cash Provided by Continuing Operating Activities | $ | 2,104 | $ | 1,578 | $ | 526 | 33.3 | % | ||||||||||||||||||
Capital Expenditures | (376) | (383) | 7 | (1.7) | % | |||||||||||||||||||||
Free Cash Flow | $ | 1,728 | $ | 1,195 | $ | 532 | 44.6 | % | ||||||||||||||||||
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 GUIDANCE RECONCILIATION
| ||||||||||||||
Full Year FY2025 | Full Year FY2026 Guidance | |||||||||||||
($ in millions) | % Change | |||||||||||||
BDX Reported Revenues from Continuing Operations | $ | 18,544 | ||||||||||||
FY2026 Reported Revenue Growth | Low single-digit plus | |||||||||||||
Illustrative Foreign Currency (FX) Impact | ~+100 basis points | |||||||||||||
FY2026 Revenue Growth (FXN) | Low single-digit | |||||||||||||
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 GUIDANCE RECONCILIATION CONTINUED | |||||||||||||||||
Full Year FY 2026 Guidance | |||||||||||||||||
Full Year FY2025 | Total Company | ||||||||||||||||
Reported Diluted Earnings per Share from Continuing Operations | $ | 3.81 | |||||||||||||||
Purchase accounting adjustments ( | 6.46 | ||||||||||||||||
Integration costs ( | 0.44 | ||||||||||||||||
Restructuring costs ( | 0.93 | ||||||||||||||||
Transaction costs ( | 0.02 | ||||||||||||||||
Separation-related items ( | 0.01 | ||||||||||||||||
Product, litigation, and other items ( | 1.75 | ||||||||||||||||
Tax impact of specified items and other tax related (( | (1.54) | ||||||||||||||||
Adjusted Diluted Earnings per Share from Continuing Operations | $ | 11.90 | |||||||||||||||
Reported % Change | + | ||||||||||||||||
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. |
(3) | Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition. |
(4) | Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters. |
(5) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects charges of |
View original content:https://www.prnewswire.com/news-releases/bd-reports-third-quarter-fiscal-2026-financial-results-302844166.html
SOURCE BD (Becton, Dickinson and Company)